Rafael Pharmaceuticals to Present at 2017 BIO International Convention
Newark, NJ, June 19, 2017 (GLOBE NEWSWIRE) -- Sanjeev Luther, Chief Operating Officer of Rafael Pharmaceuticals, Inc. (formerly Cornerstone Pharmaceuticals, Inc.), will present the company’s clinical development strategy as Rafael prepares for its upcoming pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML). Mr. Luther will also provide an overview of Rafael’s Altered Energy Metabolism Directed (AEMD) drug platform and the promising results from phase I trials of the company’s lead metabolic cancer drug, CPI-613.
Interviews with Mr. Luther are available upon request.
WHERE: Theater 2; San Diego Convention Center; 111 W Harbor Dr., San Diego, CA 92101
WHEN: June 21, 2017, 4:00 PM
CONTACT: Jacob Jonas, 973-438-3176 or jacob.jonas@rafaelpharma.com
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
